<DOC>
	<DOCNO>NCT01950234</DOCNO>
	<brief_summary>This phase II , randomize , double-blind , placebo-controlled , multi-center study evaluate safety , tolerability , efficacy adrenocorticotropic hormone ( ACTH , Acthar gel ) administer pulsed regimen consist injection three consecutive day per month patient progressive form Multiple Sclerosis ( MS ) . Patients randomly assign either ACTH arm placebo arm . The main hypothesis 1 ) pulse ACTH safe well-tolerated , 2 ) pulse ACTH slow progression clinical paraclinical measure MS progression compare placebo .</brief_summary>
	<brief_title>ACTH Progressive Forms MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Male female patient confirm diagnosis MS McDonald criterion Age &gt; /= 18 year SPMS , PPMS , PRMS phenotype , accord Lublin Reingold criterion EDSS 2.0 6.0 , inclusive Able understand consent process Known intolerance ACTH corticosteroid Diabetes mellitus , define preexist diagnosis , fast blood glucose &gt; 125 mg/dl , glycosylated hemoglobin &gt; /= 6.5 % Osteoporosis , define preexist diagnosis Tscore dualenergy xray absorptiometry ( DEXA ) scan &lt; /= 2.5 . Current serious medical condition may interfere subject 's ability complete study , pulse ACTH therapy contraindicate might complicate current therapy ( e.g. , cancer , severe psychiatric illness , chronic infection , autoimmune disorder ) Treatment cytotoxic agent ( include necessarily limit mitoxantrone , cyclophosphamide , alemtuzumab , rituximab ) within 3 year prior randomization Treatment noncytotoxic immunosuppressive agent ( include necessarily limited corticosteroid , ACTH , azathioprine , mycophenolate mofetil , methotrexate natalizumab ) within 3 month prior randomization Treatment FDAapproved firstline MS diseasemodifying therapy ( Binterferon , glatiramer acetate , fingolimod , teriflunomide dimethyl fumarate ) permit , long treatment ongoing stable least 3 month prior randomization Treatment dalfampridine compound 4aminopyridine ( 4AP ) permit long treatment ongoing stable least 3 month prior randomization Stimulant medication fatigue ( methylphenidate , modafinil , armodafinil , amantadine dextroamphetamine ) permit , subject ask take medication study visit day study procedures/assessments complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>